Sharon Moe is a Nephrology physician. ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1701 N Senate Blvd
Indianapolis, IN 462021239
Telephone
888-484-3258Provider last certified this registry record 20 Mar 2025.
Clinical trials
- Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease
Sponsor: Indiana University
- Effect of Dietary Protein Source on Phosphaturia, PTH and FGF23 in Patients With CKD 3 and 4
Sponsor: Indiana University
- The Role of Vitamin D in Immune Function in Patients With Chronic Kidney Disease (CKD) Stages 3 and 4.
Sponsor: Indiana University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year20241 payment
- Ardelyx, Inc.Program year20233 payments
- Amgen Inc.Program year20232 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
66.1%Thiazide-like diuretic17.6%Chlorthalidone80%Indapamide20%Part D<11 patientsBeta blocker13.3%Carvedilol53%Metoprolol Succinate47%Part D<11 patients+ 5 more classes in this area
Metabolism & gastrointestinal
16.8%Potassium supplement9.8%Potassium Chloride64%Klor-Con M2036%Part D<11 patientsSGLT2 inhibitor4.1%Farxiga100%Part D<11 patients+ 1 more class in this area
Genitourinary & hormones
9.8%alpha-Adrenergic Blocker9.8%Tamsulosin Hcl100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
15 NIH research awards on record, funded 1995–2026 per NIH RePORTER. The latest:
- Indiana Clinical and Translational Sciences Institute
Indiana University Indianapolis
FY2026$5,271,891UM1TR004402 - Uremic toxins and osteocyte dysfunction in CKD
Indiana University Indianapolis
FY2026$595,445R01DK138021
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”